Key result
Diabetic nephropathy is linked to significantly elevated Lp(a) and prothrombotic markers versus healthy controls.
Why the study?
Diabetic patients exhibit a hypercoagulable state that may contribute to vascular complications, but the interaction between Lp(a) and coagulation-fibrinolytic parameters in diabetic nephropathy is not fully understood.
Cross-Sectional (n=135)
No
Elevated Lp(a) correlates with markers of hypercoagulability (alpha 2PIC and TAT) in diabetic patients with nephropathy, suggesting a mechanism for increased vascular complications in this population.
Answers are grounded in this paper and cite their sources.
May link Lp(a) to diabetic hypercoagulability; hypothesis-generating and requires prospective validation.
Lipoprotein (a) (Lp(a)) is a plasma lipoprotein of high atherogenicity and competes with plasminogen at the site of plasminogen receptors. It is known that diabetic patients show a hypercoagulable state which might contribute to diabetic vascular complications. In the present study, mean levels of plasma Lp(a) and parameters of coagulation and fibrinolysis such as thrombin-antithrombin III complex (TAT) and alpha 2 plasmin inhibitor-plasmin complex (alpha 2PIC) were elevated in diabetic patients with nephropathy compared to healthy controls. A significant positive correlation was observed between the plasma levels of Lp(a) and alpha 2PIC (p < 0.05). Plasma levels of alpha 2PIC showed a significant positive correlation with those of TAT in the diabetic group, while there was no significant correlation observed in the non-diabetic group. The present results suggest that factors of Lp(a) and coagulation-fibrinolytic systems interacted, contributing to vascular complications in diabetic patients with nephropathy.
No takes yet. Share an insight, caveat, or question.
Takashi Nagai (1994) conducted a cross-sectional in Diabetes mellitus with nephropathy (n=135). Diabetes with nephropathy vs. Healthy non-diabetic controls was evaluated on Plasma levels of Lipoprotein (a) (p=<0.05). Diabetic patients with nephropathy had elevated plasma levels of Lipoprotein (a), thrombin-antithrombin III complex, and alpha2 plasmin inhibitor-plasmin complex compared to healthy controls.
Synapse has enriched 10 related papers. Consider them for comparative context: